Journal Information
Vol. 43. Issue 10.
Pages 530-534 (January 2007)
Share
Share
Download PDF
More article options
Vol. 43. Issue 10.
Pages 530-534 (January 2007)
Original Articles
Full text access
Spirometry Reference Values After Inhalation of 200 μg of Salbutamol
Visits
5541
Rogelio Pérez-Padillaa,
Corresponding author
perezpad@servidor.unam.mx

Correspondence: Dr. R. Pérez-Padilla. Instituto Nacional de Enfermedades Respiratorias. Tlalpan, 4502. 14080 Mexico City, Mexico
, Luis Torre Bouscouleta, Juan Carlos Vázquez-Garcíaa, Adriana Muiñob, María Márquezb, María Victorina Lópezb, María Montes de Ocac, Carlos Tálamoc, Gonzalo Valdiviad, Julio Pertuzed, José Jardime, Ana María B. Menezesf, on behalf of the PLATINO group *
a Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
b Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
c División Pulmonar, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela
d Pontificia Universidad Católica de Chile, Santiago, Chile
e Universidad Federal de São Paulo, São Paulo, Brazil
f Universidad Federal de Pelotas, Pelotas, Brazil
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Objective

The criteria for disease severity established by the Global Initiative for Chronic Obstructive Lung Disease are based on forced expiratory volume in 1 second (FEV1) expressed as a percentage of the predicted value after application of a bronchodilator. This study aims to determine postbronchodilator spirometry reference values.

SUBJECTS AND METHODS

A cluster sample of subjects aged 40 years or over was chosen to be representative of the metropolitan areas of 5 Latin American cities (São Paulo, Mexico City, Montevideo, Santiago, and Caracas). Spirometry was performed on 5183 subjects following the recommendations of the American Thoracic Society before and after inhalation of 200 μg of salbutamol. Multiple linear regression equations were fitted for the postbronchodilator spirometric values–FEV1, forced expiratory volume in 6 seconds (FEV6), peak expiratory flow rate, forced vital capacity (FVC), FEV1/FEV6, FEV1/FVC and forced expiratory flow between 25% and 75% of vital capacity (FEF25-75). These were adjusted for sex, age, and height in 887 asymptomatic subjects with no history of lung disease.

RESULTS

The postbronchodilator reference values for FEV1, FEV1/FVC, and FEV1/FEV6 were on average 3% higher than those obtained before bronchodilation. This apparently small difference caused an upward shift in the 5th percentile (lower limit of normal) of the predicted values. When prebronchodilation instead of postbronchodilation reference values were used, 3.2% of the results for airflow obstruction in our population of over-40-year-olds were false negatives.

CONCLUSIONS

The reported reference values are more appropriate for postbronchodilator spirometry and make it possible to reduce the number of misclassifications.

Key words:
Chronic obstructive pulmonary disease (COPD)
Bronchodilator response
Reference values
Spirometry
Cross- sectional study
Latin America
PLATINO
Objetivo

La clasificación de la gravedad de la enfermedad pulmonar obstructiva crónica (EPOC) se basa, de acuerdo con la iniciativa GOLD, en el volumen espiratorio forzado en el primer segundo (FEV1) después de usar broncodilatador, expresado como porcentaje del esperado. El propósito de este trabajo ha sido determinar los valores de referencia para la espirometría después de la administración de broncodilatador.

SUJETOS Y MÉTODOS

Se realizó un muestreo por conglomerados de sujetos de 40 años o más, representativos de las zonas metropolitanas de São Paulo, Ciudad de México, Montevideo, Santiago y Caracas. Se realizó una espirometría a 5.183 sujetos de acuerdo con las recomendaciones de la American Thoracic Society, antes y después de la inhalación de 200 μg de salbutamol. Se efectuaron regresiones lineales múltiples para los valores espirométricos –FEV1, volumen espiratorio forzado en 6 s (FEV6), índice de flujo espiratorio máximo, capacidad vital forzada (FVC), FEV1/FEV6, FEV1/FVC y flujo mesoespiratorio forzado– después del uso del broncodilatador, ajustando por sexo, edad y altura, en 887 sujetos sin evidencia de enfermedad pulmonar previa.

RESULTADOS

Los valores de referencia tras broncodilatador para FEV1, FEV1/FVC y FEV1/FEV6 fueron en promedio un 3% mayores que los obtenidos con la espirometría realizada antes de la inhalación del broncodilatador. Esta diferencia, que parece pequeña, causa un desplazamiento hacia arriba en el percentil 5 (límite inferior de la normalidad) de los valores esperados. Si se utiliza el valor de referencia prebroncodilatador, en lugar del posbroncodilatador, se genera un 3,2% de falsos negativos para obstrucción al flujo aéreo en el total de la población de 40 o más años de edad.

CONCLUSIONES

Los valores de referencia indicados son más apropiados para espirometrías realizadas después de la inhalación del broncodilatador y permiten minimizar los errores de clasificación.

Palabras clave:
EPOC
Respuesta al broncodilatador
Valores de referencia
Espirometría
Estudio transversal
Latinoamérica
PLATINO
Full text is only aviable in PDF
REFERENCES
[1]
BR Celli, W MacNee.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J, 23 (2004), pp. 932-946
[2]
GOLD.
Workshop report, global strategy for diagnosis, management and prevention of COPD.
[3]
R Pellegrino, G Viegi, V Brusasco, et al.
Interpretative strategies for lung function tests.
Eur Respir J, 26 (2005), pp. 948-968
[4]
A Johannessen, S Lehmann, ER Omenaas, et al.
Post-bronchodilator spirometry reference values in adults and implications for disease management.
Am J Respir Crit Care Med, 173 (2006), pp. 1316-1325
[5]
AM Menezes, CG Victora, R Pérez-Padilla.
The PLATINO project: methodology of a multicenter prevalence survey of chronic obstructive pulmonary disease in major Latin American cities.
BMC Med Res Methodol, 4 (2004), pp. 15
[6]
AM Menezes, R Pérez-Padilla, JR Jardim, et al.
Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study.
Lancet, 366 (2005), pp. 1875-1881
[7]
J Pérez Padilla, G Valdivia, A Muiño, et al.
Valores de referencia espirométrica en 5 grandes ciudades de Latinoamérica para sujetos de 40 o más años de edad.
Arch Bronconeumol, 42 (2006), pp. 317-325
[8]
R Pérez-Padilla, J Vázquez-García, M Márquez, et al.
The long-term stability of portable spirometers used in a multinational study of COPD prevalence.
Respir Care, 51 (2006), pp. 1167-1171
[9]
MR Miller, J Hankinson, V Brusasco, et al.
Standardisation of spirometry.
Eur Respir J, 26 (2005), pp. 319-338
[10]
American Thoracic Society.
Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society.
Am Rev Respir Dis, 144 (1991), pp. 1202-1218
[11]
JL Hankinson, JR Odencrantz, KB Fedan.
Spirometric reference values from a sample of the general U.S. population.
Am J Respir Crit Care Med, 159 (1999), pp. 179-187
[12]
StataCorp.
Stata Statistical Software: release 9.0, Stata Corporation, (2005),
[13]
American Thoracic Society.
Standardization of spirometry, 1994 update.
Am J Respir Crit Care Med, 152 (1995), pp. 1107-1136
[14]
R Pellegrino, JR Rodarte, V Brusasco.
Assessing the reversibility of airway obstruction.
Chest, 114 (1998), pp. 1607-1612
[15]
PM Tweeddale, F Alexander, GJ McHardy.
Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects.
Thorax, 42 (1987), pp. 487-490

The remaining members of the PLATINO group are listed at the end of the article.

This study was financed by a Boehringer-Ingelheim research grant. The company played no role in the data analysis or preparation of the manuscript.

Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?